758 related articles for article (PubMed ID: 26604635)
1. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
[TBL] [Abstract][Full Text] [Related]
2. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
3. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
4. The PI3K/AKT Pathway as a Target for Cancer Treatment.
Mayer IA; Arteaga CL
Annu Rev Med; 2016; 67():11-28. PubMed ID: 26473415
[TBL] [Abstract][Full Text] [Related]
5. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
Owonikoko TK; Khuri FR
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714559
[TBL] [Abstract][Full Text] [Related]
6. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
[TBL] [Abstract][Full Text] [Related]
7. The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions.
Baghery Saghchy Khorasani A; Pourbagheri-Sigaroodi A; Pirsalehi A; Safaroghli-Azar A; Zali MR; Bashash D
Eur J Pharmacol; 2021 May; 898():173983. PubMed ID: 33647255
[TBL] [Abstract][Full Text] [Related]
8. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
[TBL] [Abstract][Full Text] [Related]
9. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.
Papadimitrakopoulou V
J Thorac Oncol; 2012 Aug; 7(8):1315-26. PubMed ID: 22648207
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
11. HER2 expression and PI3K-Akt pathway alterations in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Ito M; Igarashi H; Naito T; Mitsuhashi K; Matsunaga Y; Takahashi T; Mikami M; Adachi Y; Suzuki H; Shinomura Y
Digestion; 2014; 89(1):12-7. PubMed ID: 24458107
[TBL] [Abstract][Full Text] [Related]
12. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Andersen JN; Sathyanarayanan S; Di Bacco A; Chi A; Zhang T; Chen AH; Dolinski B; Kraus M; Roberts B; Arthur W; Klinghoffer RA; Gargano D; Li L; Feldman I; Lynch B; Rush J; Hendrickson RC; Blume-Jensen P; Paweletz CP
Sci Transl Med; 2010 Aug; 2(43):43ra55. PubMed ID: 20686178
[TBL] [Abstract][Full Text] [Related]
13. Targeting PI3 kinase in cancer.
Bauer TM; Patel MR; Infante JR
Pharmacol Ther; 2015 Feb; 146():53-60. PubMed ID: 25240910
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
15. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
16. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
17. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.
Herschbein L; Liesveld JL
Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression.
Zhang CZ; Wang XD; Wang HW; Cai Y; Chao LQ
J BUON; 2015; 20(1):218-22. PubMed ID: 25778319
[TBL] [Abstract][Full Text] [Related]
20. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
